TIDMIMM
RNS Number : 9226R
Immupharma PLC
06 March 2023
6th March 2023
ImmuPharma PLC
("ImmuPharma" or the "Company")
Collaboration with Orano on ImmuPharma's peptide technology as a
vector for cancer radiotherapy
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and
development company, is delighted to announce that it has signed an
initial collaboration agreement on the Company's peptide
technology, with Orano SA ("Orano"), a leading international
corporation and a key player in the nuclear energy sector.
Key points:
-- Orano has paid a small undisclosed amount to ImmuPharma for a
12-month collaboration to identify suitable radiotherapy candidates
for the treatment of cancer.
-- ImmuPharma has agreed to provide its peptide technology, to
explore the potential to allow delivery of a potent radioactive
isotope to the core of a cancer cell.
-- Our team based in Bordeaux, (ImmuPharma Biotech), in
conjunction with Orano and the Cancer Research Centre of Lyon
(CRCL) , will work together to identify molecules that can carry
the radioactive entity.
-- Any potential new cancer therapeutic using ImmuPharma's
peptide technology, discovered as part of the collaboration will be
subject to a full licensing agreement between ImmuPharma and Orano
in preparation for further development by Orano.
-- The therapeutic goal is to use ImmuPharma's peptide
technology to deliver a radioactive bullet to the nucleus of cancer
cells, killing the cell with minimal impact on surrounding
tissue.
-- The radiopharmaceuticals market is expected to achieve global
sales *EUR8.5bn by 2031. The combination of ImmuPharma's peptide
technology and a powerful radioactive bullet is an exciting new
approach with significant commercial potential.
Further details of this development program will be communicated
over the next 12 months.
*Source: Transparency Market Research, November 2022.
Commenting on the announcement, Tim McCarthy, CEO of ImmuPharma,
said:
"We are delighted to have signed this agreement with Orano. It
is the ideal program for our peptide asset given its ability to
enter the nucleus of cancer cells. The combination of our peptide
as a nuclear targeting vector, combined with the short-range
destructive qualities of Orano's radioactive bullet makes this a
logical collaboration for both companies. Furthermore, we
potentially create a new product life cycle for our peptide. We
look forward to working with Orano and the Cancer Research Centre
of Lyon over the next 12 months ."
Commenting on the announcement, Guillaume Dureau, Orano's
Director of Research & Development and Innovation said:
"For Orano, it is a real opportunity to evaluate the potential
of a highly promising compound, combining one of our new
radioisotopes with a promising peptide previously developed by
Immupharma. This will enable us to expand and strengthen our
pipeline of innovative radiopharmaceuticals."
This announcement contains inside information as stipulated
under the UK version of the Market Abuse Regulation no 596/2014
which is part of English law by virtue of the European (withdrawal)
Act 2018, as amended. On publication of this announcement via a
regulatory information service, this information is considered to
be in the public domain.
*Ends*
For further information please contact:
ImmuPharma PLC ( www.immupharma.com ) +44 (0) 207 206 2650
Tim McCarthy, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 36 8 3550
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes, Bob Pountney +44 (0) 203 650 3650
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical
company that discovers and develops peptide-based therapeutics. The
Company's portfolio includes novel peptide therapeutics for
autoimmune diseases and anti-infectives. The lead program, P140
(Lupuzor(TM)), is a first-in class autophagy immunomodulator for
the treatment of Lupus and preclinical analysis suggest therapeutic
activity for many other autoimmune diseases that share the same
autophagy mechanism of action.
For additional information about ImmuPharma please visit
www.immupharma .co.uk
About Orano
As a recognized international operator in the field of nuclear
materials, Orano delivers solutions to address present and future
global energy and health challenges. Its expertise and mastery of
cutting-edge technologies enable Orano to offer its customers high
value-added products and services throughout the entire fuel cycle.
Every day, the Orano group's 17,000 employees draw on their skills,
unwavering dedication to safety and constant quest for innovation,
with the commitment to develop know-how in the transformation and
control of nuclear materials, for the climate and for a healthy and
resource-efficient world, now and tomorrow.
Orano, giving nuclear energy its full value. Orano looks
continuously at opportunities to value material derived from its
core nuclear energy activities in a sustainable approach. Nuclear
medicine therapy is one of the currently explored strand realized
with the production of lead-212 (a rare radioisotope used for
targeted alpha therapy) and clinical studies underway. Orano aims
to further strengthen its development in the medical field and
complete its pipeline with new promising radioisotopes.
Further information can be found at: www.orano.group
About Cancer Research Center of Lyon
The Cancer Research Centre of Lyon (CRCL, UMR Inserm 1052 - CNRS
5286 - Centre Léon Bérard) is a research structure affiliated with
the University Claude Bernard Lyon 1, the national health and
research bodies (Inserm and CNRS), the Léon Bérard Comprehensive
Cancer Centre (CLB) and with the Lyon University Hospitals (HCL) as
clinical partners. The CRCL was officially created in January 2011
and its contract was recently renewed for the 2020-2026 period. It
comprises 24 teams, totalling about 600 members, including 150
researchers and lecturers. The CRCL aims at increasing its
international visibility and the attractiveness of the Lyon cancer
research cluster, at facilitating the transfer of knowledge from
fundamental cancer research to clinical applications in oncology,
and at developing teaching and training in oncology.
Further information can be found at: www.crcl.fr
ImmuPharma's LEI (Legal Entity Identifier) code :
213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRJIMTTMTBMBAJ
(END) Dow Jones Newswires
March 06, 2023 02:00 ET (07:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Nov 2024 to Dec 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Dec 2023 to Dec 2024
